Thermeutics was founded by Dr. Syed Faaiz Enam, a physician-scientist who watched glioblastoma claim patients despite the best available treatments. Trained as a neurologist at Duke and completing his Neuro-Oncology fellowship at UCLA, Faaiz asked a different question: what if we could simply stop tumor cells from dividing by cooling them?

The answer came from physics. At 25°C — room temperature — glioblastoma cells stop growing. The brain tolerates local cooling. And an implantable device could deliver precisely that cooling, continuously and locally, while patients receive standard chemotherapy and radiation.

In 2022, Dr. Enam published the foundational science in Science Advances, demonstrating cytostatic hypothermia in rodents. Rats receiving full-dose cooling survived their entire study period with no deaths — a striking result compared to untreated controls. The pig experiments followed, validating safe and sustained cooling in an awake, freely-moving large animal.

Today, Thermeutics is building Stasis — the world’s first implantable focal cooling system designed specifically for glioblastoma. Our mission is to buy time, preserve brain function, and ultimately extend lives for the 13,000 Americans diagnosed each year.